Lehtinen A, Leirisalo-Repo M, Taavitsainen M
Department of Radiology, Helsinki University Central Hospital, Finland.
Clin Exp Rheumatol. 1995 Nov-Dec;13(6):733-6.
The persistence of enthesopathic changes was studied by ultrasound (US) in 23 patients with spondylarthropathy during a 6-month prospective trial with sulphasalazine (Salazopyrin). During the follow-up significant improvement was seen in the joint symptoms and in the laboratory variables. By US 78% of the patients had enthesopathy at entry and 74% after 6 months of follow-up. The plantar fascia was the enthesis most frequently affected. Treatment with sulphasalazine had no obvious influence on the persistence of enthesopathy. Enthesopathy is as a rule a constant phenomenon and is probably caused by chronic enthesitis. A parallel resolution of anatomic soft tissue changes and the clinical status was not seen on US. There was also no evidence of a favourable effect of sulphasalazine on enthesopathy in the 6-month follow-up.
在一项为期6个月的柳氮磺胺吡啶（Salazopyrin）前瞻性试验中，通过超声（US）对23例脊柱关节病患者的附着点病变化持续性进行了研究。在随访期间，关节症状和实验室指标有显著改善。超声检查显示，78%的患者在入组时有附着点病，随访6个月后这一比例为74%。足底筋膜是最常受影响的附着点。柳氮磺胺吡啶治疗对附着点病的持续性没有明显影响。附着点病通常是一种持续存在的现象，可能由慢性附着点炎引起。超声检查未发现解剖学软组织变化与临床状况的平行缓解。在6个月的随访中，也没有证据表明柳氮磺胺吡啶对附着点病有有利影响。
